Trending Now
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Announces Important Upcoming Milestones
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has announced its Q3 2020 results and also offered a corporate update.
BioCryst ready to launch ORLADEYO
Jon Stonehouse, the CEO and...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Axovant Gene Therapies Ltd. (NASDAQ:AXGT) Partners With Viralgen To Scale Production...
Axovant Gene Therapies Ltd. (NASDAQ:AXGT) has announced the signing of a strategic partnership with leading Contract Development and Manufacturing Organisation, Viralgen.
Partnership to help Axovant...
MAKE IT MODERN
LATEST REVIEWS
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) To Present XPOVIO® Clinical Data At 2020...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced the selection of four abstracts for poster presentation at the 2020 virtual European Society for Medical Oncology Congress.
Karyopharm...
MAKE IT MODERN
PERFORMANCE TRAINING
Top Managers See 2022 as Banner Year for Oil Stocks (PXD, FANG, CEI, HES,...
As we kick off 2022, it’s worth noting that Blackrock’s legendary investment manager, Byron Wien, once again put out his Top Ten...
Why Cannabinoid Stocks Could Emerge as 2022’s Big Winners (GLASF, SGMD, INM, CRON, AVCNF,...
As growth stocks take a hit to start off 2022, some of the most profound growth investment themes are on sale.
Cancer is Still the Real Global Health Crisis… Four Stocks with Answers (EXEL, BMY,...
While Covid-19 continues to steal the headlines, the multi-century pandemic known as Cancer still deserves the brunt of our attention. And it’s getting it....
Juvenescence Ltd. Makes a $24.6 Million Payment in Cash to Lineage Cell Therapeutics Inc....
Lineage Cell Therapeutics Inc. (NYSEAMERICAN:LCTX) has three important clinical programs, which remaking airwaves in billion-dollar markets. They include OpRegen® in Phase 1/2a development as...
Atara Biotherapeutics Inc. (NASDAQ:ATRA) Presents Positive ATA188 Study Data Showing Safety and Sustained Disability...
Atara Biotherapeutics Inc. (NASDAQ:ATRA) has announced the release of efficacy and safety data of its First Phase ATA 188 study in progressive forms of...
MAKE IT MODERN
